NCT05948761CompletedPhase 1/2
Safety and Effectiveness of Intermittent Hypoxia Treatment in Parkinson's Disease
A Randomized Phase 1b-2a Trial of the Safety and Effectiveness of Intermittent Hypoxia Treatment in Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 11 Aug 2025
Brief summary (registry, in English)
To explore the safety, feasibility and net symptomatic effects of multiple (3x/week, for 4 weeks) intermittent hypoxia treatment sessions in individuals with PD. Secondary outcomes include exploring induction of relevant neuroprotective pathways as measured in serum.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 20 Jun 2023
- Start date
- 4 Jul 2023
- Primary completion date
- 30 Aug 2024
- Lead sponsor
- Radboud University Medical Center
- Diseases
- Parkinson disease
- NCT number
- NCT05948761
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 40
- From 4 Jul 2023 to the primary completion date, 30 Aug 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Individuals with shortness of breath or other airway or breathing-related inconvenience related to lack of dopaminergic medication
Other illness
- Individuals with diseases leading to restrictive and obstructive pulmonary diseases, sleep apnea and cardiac output deficits, such as pulmonary fibrosis, COPD, sleep apnea or excessive alcoholic intake, and congestive heart failure respectively
- Individuals with coronary artery disease NYHA classes III and IV
Other
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Arterial blood gas abnormalities at screening procedure
- Inability for in-clinic measurements in OFF phase
- Individuals with active deep brain stimulation
Who the study is looking for
- Informed consent
- Clinical diagnosis of Parkinson's disease by a movement disorder specialized neurologist.
- Hoehn and Yahr staging 1 to and including 3 (indicating mild to moderate PD).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dpt. of Physiology, Radboud University Medical Center Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
| Radboud University Medical Center Coordinator of this site? Confirm its status | Nijmegen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.